All In Biotech

Drug Trial Radar · NCT03463187

Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis

A Multi-Center, Randomized, Double-blind, Placebo-controlled, Multi-Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of SHR-1314 With Expanded Dose Finding in Subjects With Moderate-to-severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Aug 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 211 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

211

Actual

Start

Dec 15, 2017

Primary completion

Aug 31, 2020

Study completion Aug 31, 2020

Sponsor

Sponsor type
Industry
First posted
Mar 13, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-regional, randomized, double-blind, placebo-controlled, clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SHR-1314 in adults with moderate-to-severe plaque psoriasis.

Conditions

  • Moderate-to-severe Chronic Plaque Psoriasis

Interventions

  • SHR-1314Biological

    Administered subcutaneously

  • PlaceboDrug

    Administered subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Clinically Significant Events (Part A)Time frame: From baseline through 24 weeks
  2. Pharmacokinetics (PK) of SHR-1314 (Part A)Time frame: From baseline through 24 weeks
  3. Pharmacokinetics (PK) of SHR-1314 (Part A)Time frame: From baseline through 24 weeks
  4. Percentage of Participants With Anti-SHR-1314 Antibodies (Part A)Time frame: From baseline through 24 weeks
  5. Percentage of subjects who achieve Psoriasis Area Severity Index (PASI) score 75 (Part B)Time frame: From baseline through 12 weeks

Locations

13 sites in 3 countries. Site status is shown where the registry gives one.

  • Elite Clinical Studies, LLC

    Phoenix, Arizona

  • Anaheim Clinical Trials

    Anaheim, California

  • Revival Research

    Doral, Florida

  • Indago Research and Health Center - Emergency Medicine

    Hialeah, Florida

  • Great Lakes Clinical Trials LLC

    Chicago, Illinois

  • Clinical Partners, LLC

    Johnston, Rhode Island

  • Center for Clinical Studies

    Houston, Texas

  • Center for Clinical Studies

    Webster, Texas

  • St George Dermatology and Skin Cancer Centre - Dermatology

    Kogarah, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Veracity Clinical Research Pty Ltd

    Woolloongabba, Queensland, Australia

  • Sinclair Dermatology - Dermatology

    East Melbourne, Victoria, Australia

  • Shanghai Huanshan Hospital Fudan University-Dermatology

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.